摘要
目的总结国内、外雷替曲塞治疗晚期结直肠癌的研究结果,综合评价雷替曲塞治疗晚期结直肠癌的临床疗效。方法采用Meta分析方法,制定原始文献的纳入标准、排除标准及检索策略,检索PubMed、EMBASE、Ovid、Springer、中国期刊全文数据库、中国生物医学文献数据库、万方数据资源系统等,获得雷替曲塞治疗晚期结直肠癌的原始文献。使用Juni量表进行文献质量评价后,采用RevMan4.22软件对满足纳入标准的随机对照研究进行Meta分析。选取患者随访终点无疾病进展生存率、死亡率和治疗有效率作为观察指标,进行定量综合评估。结果共检索出241篇文献,符合纳入标准的7篇RCT研究进入Meta分析,纳入研究均未采用盲法,文献质量评价5篇为A级,2篇为C级,有发表偏倚。Meta分析结果显示,雷替曲塞组和其他化疗方案组比较:随访终点无疾病进展生存率显著增加(RR=1.15,95%CI:1.03～1.28),随访终点死亡率和治疗有效率无显著差异(均P>0.05)。结论雷替曲塞较其他化疗方案治疗晚期结直肠癌能显著增加无疾病进展生存率。
AIM To determine the effect of raltitrexed on advanced colorectal cancer.METHODS Using Meta-analysis method,randomised controlled trials evaluating raltitrexed on advanced colorectal cancer were searched in PubMed,EMBASE,Ovid,Springer,CNKI and Wanfang database with the terms＂raltitrexed or tomude and colorectal cancer＂.The primary outcome measure was time to progression-free survival,mortality and effective rate.RESULTS Two hundred and forty-one trials were found and seven trials were included in the analysis.All studies included were not blinded.Five trials are A level and two trials are C level.There is publication bias.Overall,compared with other treatments,there is evidence of a significant beneficial effect of raltitrexed on time to progression-free survival in advanced colorectal cancer patients（RR = 1.15,95%CI：1.03-1.28）.However,raltitrexed have no effects on mortality and effective rate in advanced colorectal cancer patients（P 0.05）.CONCLUSION In general,raltitrexed seems to have a beneficial effect on the time to progression-free survival in advanced colorectal cancer patients.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2010年第11期853-857,共5页
Chinese Journal of New Drugs and Clinical Remedies
